QiLu Pharmaceutical's Iruplinalkib Phase III INSPIRE Study Researched Primary Endpoint and was Selected for 2023 WCLC Oral Presentation



JINAN, China, Aug. 17, 2023 /PRNewswire/ — August 16, 2023, at the 2023 World Conference on Lung Cancer (WCLC), the complete list of selected abstracts was announced, among which QiLu Pharmaceutical’s iruplinalkib phase III clinical trial (INSPIRE) results were chosen for oral…

Leave a Reply